Agilvax teams with Humabs BioMed on vaccine development; IDRI nets $4M from BARDA for adjuvant hub;

> New Mexico's Agilvax and Switzerland's Humabs BioMed have agreed to collaborate on vaccine development. Release

> IDRI has received $4 million from the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to develop an adjuvant manufacturing hub. Release

> Wellcome Trust and the University of Minnesota's Center for Infectious Disease Research and Policy (CIDRAP) have released guidelines for fast-tracking Ebola vaccine development. More

> GlaxoSmithKline ($GSK) has granted $350,000 to the International AIDS Vaccine Initiative (IAVI) to support implementation of the Human Vaccines Project, a public-private partnership looking to address key challenges in vaccine development. Release

> The seasonal flu vaccine induces antibodies that can protect against H7N9 avian influenza, a study has found. Report

> A new study has found GlaxoSmithKline's ($GSK) HPV vaccine Cervarix highly effective against multiple cancer-causing strains. More

And Finally... Scientists have used genetically engineered algae to produce a potential malaria vaccine candidate. More

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.